Ketamine

English name ketamine

also known as Ketamine Hydrochloride · ketalar · KET · ketamine HCl · S (+) Ketamine · PMI-150 · R,S-ketamine · Racemic ketamine · +29 more

Small molecule targets TNF via inhibition

Developed for: major depressive disorder · depressive disorder · post-traumatic stress disorder · chronic pain syndrome · bipolar depression · neuropathy, painful · sickle cell disease · substance-related disorder
+138 more
· cancer · delirium · alcohol dependence · bipolar disorder · traumatic brain injury · anxiety · obsessive-compulsive disorder · postpartum depression · opiate dependence · bipolar I disorder · bipolar II disorder · breast cancer · complex regional pain syndrome · epilepsy · abscess · alcohol-related disorders · dental caries · head and neck cancer · headache disorder · infectious disease with sepsis · Parkinson disease · atypical depressive disorder · cocaine dependence · cognitive disorder · disease of bone structure · endometriosis · head and neck carcinoma · mucositis · nicotine dependence · substance abuse · anorexia nervosa · anxiety disorder · autism spectrum disorder · benign shuddering attacks · borderline personality disorder · brain injury · cardiac arrest · cataract · cholelithiasis · cluster headache syndrome · cognitive impairment with or without cerebellar ataxia · epilepsy with generalized tonic-clonic seizures · fibromyalgia · gallbladder disorder · idiopathic scoliosis · intracranial hypertension · lung cancer · migraine disorder · mixed anxiety and depressive disorder · musculoskeletal system disorder · neuralgia · obstetric disorder · obstructive sleep apnea syndrome · osteoarthritis, knee · respiratory underresponsiveness to hypoxia and hypercapnia · subarachnoid hemorrhage · supratentorial cancer · acquired aneurysmal subarachnoid hemorrhage · acute asthma · acute kidney injury · acute respiratory failure · acute stress disorder · ADNP-related multiple congenital anomalies - intellectual disability - autism spectrum disorder · adolescent idiopathic scoliosis · alcohol abuse · alcohol withdrawal · anal fistula · anogenital human papillomavirus infection · asthma · brachial plexus neuropathy from injury · cancer or benign tumor · cancer-related condition · chemotherapy-induced oral mucositis · cleft lip/palate · complex regional pain syndrome type 1 · COVID-19 · diabetic neuropathy · digestive system cancer · drug allergy · drug-induced akathisia · drug-induced dyskinesia · dwarfism thin bones multiple fractures · epilepsy syndrome · female reproductive system disorder · hemorrhoid · hepatic infarction · hypertensive disorder · hypospadias · ischemic stroke · long COVID-19 · methamphetamine dependence · mood disorder · movement disorder · multiple sclerosis · myalgic encephalomeyelitis/chronic fatigue syndrome · nasal disorder · opioid abuse · osteoarthritis, hip · pain agnosia · perinatal disease · peripheral neuropathy · persian gulf syndrome · pharyngitis · psychiatric disorder · radiation-induced neuropathy · Rett syndrome · rotator cuff syndrome · sleep disorder · snakebite envenomation · social phobia · status asthmaticus · stroke disorder · subacute delirium · subjective cognitive decline · tinnitus · toxic polyneuropathy · traumatic encephalopathy · trigeminal neuralgia · upper thoracic spina bifida aperta · uterine disorder · ventricular septal defect · bone disorder · brachial plexus neuropathy · bronchial disorder · cardiac valvular defect · childhood malignant neoplasm · diabetic polyneuropathy · esophageal varices with bleeding · hemopneumothorax · hypotensive disorder · impacted teeth, multiple · mouth disorder · myopathy, congenital, with respiratory insufficiency and bone fractures · nephroma · neurological pain disorder · postherpetic neuralgia · refractory malignant neoplasm · urinary tract obstruction
Investigated by: National Institute of Mental Health (NIMH) · Yale University · Assiut University · Massachusetts General Hospital · Icahn School of Medicine at Mount Sinai · New York State Psychiatric Institute
+599 more
· Mayo Clinic · Tanta University · Assistance Publique - Hôpitaux de Paris · Washington University School of Medicine · Ain Shams University · Cairo University · Brooke Army Medical Center · University Health Network, Toronto · Stanford University · Tel-Aviv Sourasky Medical Center · The University of Texas Health Science Center, Houston · United States Department of Defense · VA Office of Research and Development · Sohag University · University of British Columbia · University of Saskatchewan · University of Texas Southwestern Medical Center · University of Utah · Antonios Likourezos · Javelin Pharmaceuticals · King's College London · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Mahidol University · Medical University of South Carolina · Minneapolis Veterans Affairs Medical Center · NYU Langone Health · Rebecca Price · Seoul National University Hospital · University Hospital, Clermont-Ferrand · University of Michigan · VA Connecticut Healthcare System · Columbia University · Federal University of Goiás · Isfahan University of Medical Sciences · James Murrough · Johns Hopkins University · Medical College of Wisconsin · National Center for Advancing Translational Sciences (NCATS) · National Institutes of Health (NIH) · Northwell Health · St Patrick's Hospital, Ireland · University of New Mexico · University of Wisconsin, Madison · Wake Forest University Health Sciences · Yonsei University · Zagazig University · iX Biopharma Ltd. · Aga Khan University · Ajou University School of Medicine · American Foundation for Suicide Prevention · Baylor College of Medicine · Beth Israel Deaconess Medical Center · Brain & Behavior Research Foundation · Brigham and Women's Hospital · Cedars-Sinai Medical Center · Children's Hospital Medical Center, Cincinnati · Corewell Health East · Emory University · Hospices Civils de Lyon · Hospital de Clinicas de Porto Alegre · Joshua Rosenblat · Liaquat National Hospital & Medical College · Mansoura University · Mexican Social Security Institute · Nantes University Hospital · National Alliance for Research on Schizophrenia and Depression · National Cancer Institute (NCI) · National Institute of General Medical Sciences (NIGMS) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · National Institute on Drug Abuse (NIDA) · National Taiwan University Hospital · Queen's University · Rhode Island Hospital · The Ketamine Research Foundation · all 605 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	KETALAR	—	1982-06-11	fda.gov ↗
Approved	US (FDA)	KETALAR	—	1970-02-19	fda.gov ↗

Trials 797 · started per year

today

US approved 1970

19671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049205020512052205320542055205620572058205920602061206220632064206520662067206820692070207120722073207420752076207720782079208020812082208320842085208620872088208920902091209220932094209520962097209820992100210121022103

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 043 trials · 1 met primary · 1 missed
Phase 0	NCT06378528	Sep 2026 → Sep 2027	post-traumatic stress disorder	University of Wisconsin, Madison	Suspended	No outcome recorded Stop: Business
Phase 0	NCT07211399	Jul 2026 → Dec 2030	substance-related disorder	Jacques E. Chelly	Withdrawn	No outcome recorded Stop: Business
Phase 0	NCT06062628	Jun → Dec 2026	traumatic brain injury, traumatic encephalopathy	University of Texas Southwestern Medical Center	Withdrawn	No outcome recorded Stop: Enrollment
Phase 0	NCT07294092	Apr 2026 → Aug 2028 expected	—	Keith M Vogt	Recruiting	No outcome recorded
Phase 0	NCT06788249	Apr → Dec 2026 expected	major depressive disorder	University of Pennsylvania	Recruiting	No outcome recorded
Phase 0	NCT07429916	Jan → Jun 2026 overdue	—	King Abdullah University Hospital	Recruiting	No outcome recorded
Phase 0	NCT06935552	Jun 2025 → Nov 2026 expected	—	Assiut University	Not yet recruiting	No outcome recorded
Phase 0	NCT06665568	Apr → Dec 2025 overdue	anxiety, major depressive disorder, sleep disorder	University of Zurich	Not yet recruiting	No outcome recorded
Phase 0	NCT07040163	Mar 2025 → Feb 2026 overdue	—	CAMC Health System	Active not recruiting	No outcome recorded
Phase 0	NCT05344625	Oct 2023 → Mar 2024	anxiety disorder, cancer-related condition, depressive disorder	Northwell Health	Withdrawn	No outcome recorded
Phase 0	NCT06001372	Oct → Dec 2023	anxiety, depressive disorder, digestive system cancer	University of Utah	Terminated	No outcome recorded
Phase 0	NCT05410158	May → Jul 2023	—	Assiut University	Unknown	No outcome recorded
Phase 0	NCT05796791	May 2023 → Jun 2024	nicotine dependence	Medical University of South Carolina	Completed	No outcome recorded
Phase 0	NCT05505630	Jan 2023 → Dec 2025	nicotine dependence	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 0	NCT05327699	Nov 2022 → Mar 2028 expected	major depressive disorder	Emory University	Recruiting	No outcome recorded
Phase 0	NCT05086250	Oct 2022 → Jul 2026 overdue	anxiety, malignant pancreatic neoplasm	Cedars-Sinai Medical Center	Recruiting	No outcome recorded
Phase 0	NCT05468047	Sep 2022 → Sep 2024	perceptual disorders	Integrative Psychiatry Institute	Unknown	No outcome recorded
Phase 0	NCT04928703	May → Dec 2022	—	ERP Biomarker Qualification Consortium	Completed	No outcome recorded
Phase 0	NCT05217706	Mar 2022 → Jan 2024	depressive disorder	Rady Children's Hospital, San Diego	Unknown	No outcome recorded
Phase 0	NCT06807554	Jan 2022	—	Liaquat National Hospital & Medical College	Completed	Met primary
Phase 0	NCT04977674	Sep 2021 → Feb 2023	major depressive disorder	King's College London	Completed	No outcome recorded
Phase 0	NCT05097118	Sep 2021 → May 2022	appendicitis	Sohag University	Completed	No outcome recorded
Phase 0	NCT04712071	Feb 2021 → Feb 2022	persian gulf syndrome	Baylor College of Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 0	NCT04562779	Jan 2021 → Jan 2022	alcohol dependence	Denver Health and Hospital Authority	Completed	Missed primary
Phase 0	NCT04413799	Sep 2020 → Dec 2024	—	George Washington University	Terminated	No outcome recorded Stop: Enrollment
Phase 0	NCT03788694	Jan 2020	—	Bronx Veterans Medical Research Foundation, Inc	Withdrawn	No outcome recorded Stop: Enrollment
Phase 0	NCT04285684	Dec 2019 → Jan 2021	lactation disease	The Ketamine Research Foundation	Completed	No outcome recorded
Phase 0	NCT04022226	Oct 2019 → Oct 2020	—	University of New Mexico	Completed	No outcome recorded
Phase 0	NCT04099771	Jul 2019 → Dec 2021	major depressive disorder	The Miriam Hospital	Unknown	No outcome recorded
Phase 0	NCT03885427	Mar → May 2019	—	Zagazig University	Completed	No outcome recorded
Phase 0	NCT03896256	Mar 2019 → Jan 2020	migraine disorder	Thomas Jefferson University	Completed	No outcome recorded
Phase 0	NCT03573349	Jan 2019 → Dec 2026 expected	bipolar depression, major depressive disorder	Mayo Clinic	Active not recruiting	No outcome recorded
Phase 0	NCT03067974	Sep 2017 → Jan 2019	—	University of Arizona	Terminated	No outcome recorded
Phase 0	NCT03090776	Jul 2017 → Sep 2025	chronic pain syndrome, neuropathy, painful	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 0	NCT02836288	Dec 2016 → May 2018	cancer, depressive disorder	Scott A. Irwin, MD, PhD	Completed	No outcome recorded
Phase 0	NCT02442739	Aug 2016 → Nov 2017	depressive disorder, head and neck cancer, malignant pancreatic neoplasm	Cedars-Sinai Medical Center	Withdrawn	No outcome recorded Stop: Enrollment
Phase 0	NCT02593643	Jan 2016 → Apr 2017	bipolar I disorder, bipolar II disorder, bipolar depression, major depressive disorder	Sunnybrook Health Sciences Centre	Completed	No outcome recorded
Phase 0	NCT02414932	Apr 2015 → Apr 2017	depressive disorder	St Patrick's Hospital, Ireland	Completed	No outcome recorded
Phase 0	NCT02083926	Jan 2015 → Sep 2016	social phobia	Yale University	Completed	No outcome recorded
Phase 0	NCT03609190	Jan 2015 → Dec 2018	major depressive disorder	Psychiatric University Hospital, Zurich	Completed	No outcome recorded
Phase 0	NCT02317341	Dec 2014 → Mar 2019	cancer	National Institute of Nursing Research (NINR)	Terminated	No outcome recorded
Phase 0	NCT02037035	Jul 2013 → Jun 2021	depressive disorder	Yale University	Completed	No outcome recorded
Phase 0	NCT03842800	Apr 2013 → Aug 2018	cognitive impairment with or without cerebellar ataxia	Yale University	Completed	No outcome recorded

Phase 176 trials · 1 missed
Phase 1	NCT07683988	Oct 2026 → Aug 2027 expected	major depressive disorder	Western University, Canada	Not yet recruiting	No outcome recorded
Phase 1	NCT07691372	Jun → Jul 2026 overdue	—	iX Biopharma Ltd.	Not yet recruiting	No outcome recorded
Phase 1	NCT05575999	Jan → Oct 2026 expected	—	Kansas City Heart Rhythm Research Foundation	Not yet recruiting	No outcome recorded
Phase 1	NCT07307768	Dec 2025 → Dec 2027 expected	—	Soterix Medical	Not yet recruiting	No outcome recorded
Phase 1	NCT06919198	Sep 2025 → Aug 2028	—	University of Wisconsin, Madison	Withdrawn	No outcome recorded
Phase 1	NCT06935669	Apr 2025 → Apr 2026 overdue	—	Ain Shams University	Not yet recruiting	No outcome recorded
Phase 1	NCT06767566	Mar 2025 → Dec 2027 expected	postpartum depression	University of Utah	Recruiting	No outcome recorded
Phase 1	NCT06772753	Feb 2025 → Jun 2027 expected	—	Johns Hopkins University	Recruiting	No outcome recorded
Phase 1	NCT06698848	Jan 2025 → Jun 2030 expected	depressive disorder	Massachusetts General Hospital	Active not recruiting	No outcome recorded
Phase 1	NCT06966596	Nov 2024 → Mar 2025	gallbladder disorder	Fazaia Ruth Pfau Medical College	Completed	No outcome recorded
Phase 1	NCT06085937	May 2024 → Apr 2026 overdue	depressive disorder	Lindsay Maguire, MD	Recruiting	No outcome recorded
Phase 1	NCT05962424	Oct 2023 → Sep 2030 expected	psychiatric disorder	Stanford University	Recruiting	No outcome recorded
Phase 1	NCT06138691	Oct 2023 → Jan 2025	—	Washington University School of Medicine	Completed	No outcome recorded
Phase 1	NCT05907213	Sep 2023 → Jun 2024	postpartum depression	Grace Lim, MD, MS	Completed	No outcome recorded
Phase 1	NCT06631625	Sep 2023 → Sep 2024	—	Alexandria University	Completed	No outcome recorded
Phase 1	NCT05915013	Sep 2023 → Dec 2032 expected	major depressive disorder, post-traumatic stress disorder	Yale University	Recruiting	No outcome recorded
Phase 1	NCT05378555	May 2023 → Nov 2025	sickle cell disease	Boston Children's Hospital	Completed	No outcome recorded
Phase 1	NCT05401227	Oct 2022 → Aug 2028 expected	—	New York State Psychiatric Institute	Recruiting	No outcome recorded
Phase 1	NCT05320107	Jun 2022 → Feb 2025	major depressive disorder	Medical University of Vienna	Unknown	No outcome recorded
Phase 1	NCT05229653	Apr → Oct 2022	endometriosis	NYU Langone Health	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT05051449	Apr 2022 → Nov 2023	depressive disorder, substance-related disorder	University of Maryland, Baltimore	Terminated	No outcome recorded Stop: Business
Phase 1	NCT04861051	Jul 2021 → Aug 2028 expected	epilepsy	Stanford University	Recruiting	No outcome recorded
Phase 1	NCT04941040	Jul → Oct 2021	supratentorial cancer	Kasr El Aini Hospital	Completed	No outcome recorded
Phase 1	NCT04714541	Apr 2021 → Jul 2022	anorexia nervosa	Homeostasis Therapeutics, LLC	Completed	No outcome recorded
Phase 1	NCT05536362	Feb 2021 → Jan 2022	colon carcinoma	Egymedicalpedia	Completed	No outcome recorded
Phase 1	NCT04876066	Nov 2020 → Nov 2022	—	West Virginia University	Unknown	No outcome recorded
Phase 1	NCT04429685	Nov 2020 → May 2021	—	University of Texas Southwestern Medical Center	Terminated	No outcome recorded Stop: Business
Phase 1	NCT04587778	Oct 2020 → Mar 2025	major depressive disorder	Medical University of Vienna	Unknown	No outcome recorded
Phase 1	NCT04205890	May 2020	depressive disorder	Neurological Associates of West Los Angeles	Withdrawn	No outcome recorded Stop: Business
Phase 1	NCT03973268	Jan 2020 → Feb 2027 expected	major depressive disorder	National Institute of Mental Health (NIMH)	Recruiting	No outcome recorded
Phase 1	NCT04082858	Jan → Jun 2020	major depressive disorder	St Patrick's Hospital, Ireland	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT04409665	Jan 2020 → Mar 2022	newborn respiratory distress syndrome	Medical University of Warsaw	Unknown	No outcome recorded
Phase 1	NCT05421962	Jan 2020 → Dec 2021	—	Cantonal Hospital Zenica	Completed	No outcome recorded
Phase 1	NCT04032301	Sep 2019 → Sep 2024	major depressive disorder, post-traumatic stress disorder	University of Minnesota	Completed	No outcome recorded
Phase 1	NCT04199468	Sep 2019 → Jun 2022	—	Yale University	Completed	No outcome recorded
Phase 1	NCT06021756	Jul 2019 → Aug 2022	Parkinson disease, drug-induced dyskinesia	University of Arizona	Unknown	No outcome recorded
Phase 1	NCT03977675	May 2019 → Jul 2020	major depressive disorder	Columbia University	Terminated	No outcome recorded
Phase 1	NCT03860831	Mar → Jun 2019	—	Ain Shams University	Unknown	No outcome recorded
Phase 1	NCT03792672	Feb → May 2019	—	Neurocrine Biosciences	Completed	Mixed
Phase 1	NCT03721900	Dec 2018 → Jun 2019	major depressive disorder	Shenox Pharmaceuticals, LLC	Unknown	No outcome recorded
Phase 1	NCT03367533	Nov 2018 → Jul 2022	bipolar disorder, major depressive disorder, post-traumatic stress disorder	Yale University	Completed	No outcome recorded
Phase 1	NCT03799900	Nov 2018 → Mar 2019	substance abuse	Naurex, Inc	Completed	No outcome recorded
Phase 1	NCT03933865	Oct 2018 → Feb 2022	opiate dependence	University of California, San Francisco	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT05444036	Sep 2018 → May 2019	—	Egymedicalpedia	Completed	No outcome recorded
Phase 1	NCT03469089	Mar → May 2018	schizophrenia	University of Eastern Finland	Unknown	No outcome recorded
Phase 1	NCT03256162	Sep 2017 → Sep 2018	bipolar depression, major depressive disorder	St Patrick's Hospital, Ireland	Completed	Missed primary
Phase 1	NCT03065335	May 2017 → Jan 2027 expected	major depressive disorder	National Institute of Mental Health (NIMH)	Recruiting	No outcome recorded
Phase 1	NCT02652507	Jun 2016 → May 2018	—	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 1	NCT03017248	Jan → Jun 2016	—	Faculty of Medicine, Sousse	Unknown	No outcome recorded
Phase 1	NCT02611921	Dec 2015 → May 2018	autism spectrum disorder	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 1	NCT02661061	Dec 2015 → May 2018	major depressive disorder	St Patrick's Hospital, Ireland	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT02515890	Nov 2015 → Dec 2018	amnestic disorder	University of Pittsburgh	Completed	No outcome recorded
Phase 1	NCT02501941	Jul 2015 → Jan 2017	subarachnoid hemorrhage, traumatic brain injury	University of New Mexico	Completed	No outcome recorded
Phase 1	NCT02708849	Jun 2015 → Mar 2020	mental disorder	Yale University	Terminated	No outcome recorded
Phase 1	NCT02577250	May 2015 → Jun 2016	major depressive disorder, post-traumatic stress disorder	Minneapolis Veterans Affairs Medical Center	Completed	No outcome recorded
Phase 1	NCT02289248	Feb 2015 → Oct 2016	depressive disorder	Yale University	Completed	No outcome recorded
Phase 1	NCT02341963	Jan 2015 → Dec 2020	—	Rush University Medical Center	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT02494830	Aug → Sep 2014	—	University Medicine Greifswald	Completed	No outcome recorded
Phase 1	NCT02165449	Jun 2014 → Aug 2019	major depressive disorder	University of California, Los Angeles	Completed	No outcome recorded
Phase 1	NCT02033434	Mar 2014 → May 2016	—	University of Calgary	Completed	No outcome recorded
Phase 1	NCT01740492	Sep 2012 → Jun 2014	—	Rhode Island Hospital	Completed	No outcome recorded
Phase 1	NCT01551329	Mar 2012 → Nov 2015	alcohol dependence, major depressive disorder	Yale University	Completed	No outcome recorded
Phase 1	NCT01500018	Jan → Apr 2012	substance abuse	AstraZeneca	Withdrawn	No outcome recorded Stop: Business
Phase 1	NCT02378415	Dec 2011 → Jun 2013	depressive disorder	United States Naval Medical Center, San Diego	Terminated	No outcome recorded
Phase 1	NCT01435213	Sep 2011 → Jan 2012	—	University of Turku	Completed	No outcome recorded
Phase 1	NCT01369680	May 2011 → Oct 2012	chronic pain syndrome	University of Rochester	Completed	No outcome recorded
Phase 1	NCT01209845	Apr → Dec 2010	depressive disorder	Yale University	Completed	No outcome recorded
Phase 1	NCT01165294	Oct 2009 → May 2010	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 1	NCT01736020	Sep 2009 → Apr 2017	—	Southern California Institute for Research and Education	Unknown	No outcome recorded
Phase 1	NCT02675530	Dec 2007 → Dec 2011	schizophrenia	Yale University	Completed	No outcome recorded
Phase 1	NCT00662883	Nov 2007 → Feb 2008	—	Javelin Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00548964	Oct 2007 → Jul 2013	major depressive disorder	James Murrough	Completed	No outcome recorded
Phase 1	NCT00520104	Aug 2007 → Feb 2008	—	Javelin Pharmaceuticals	Unknown	No outcome recorded
Phase 1	NCT00520169	Jul → Sep 2007	—	Javelin Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00519987	Jun → Aug 2007	—	Javelin Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00618397	Jun 2006 → Jun 2015	substance-related disorder	University of Texas Southwestern Medical Center	Terminated	No outcome recorded Stop: Enrollment

Phase 1/235 trials · 2 met primary · 2 missed
Phase 1/2	NCT07009158	Mar 2026 → Sep 2029 expected	chronic pain syndrome, post-traumatic stress disorder	Dr. Yuliya Knyahnytska	Recruiting	No outcome recorded
Phase 1/2	NCT07443254	Mar 2026 → Apr 2027 expected	—	CAMC Health System	Recruiting	No outcome recorded
Phase 1/2	NCT07180095	Jan → Jun 2026 overdue	—	Liaquat National Hospital & Medical College	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07247370	Dec 2025 → Apr 2027 expected	alcohol-related disorders, major depressive disorder	South West Sydney Local Health District	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07482709	Nov 2025 → Mar 2026 overdue	—	Liaquat National Hospital & Medical College	Recruiting	No outcome recorded
Phase 1/2	NCT06597695	Jul 2025 → Jul 2027 expected	depressive disorder	Juliana Zambrano, MD, MPH	Recruiting	No outcome recorded
Phase 1/2	NCT05991232	May 2025 → Apr 2028	depressive disorder	Jay Fournier	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1/2	NCT06090422	Jan 2025 → Jul 2027 expected	alcohol-related disorders, depressive disorder	University Hospital of North Norway	Recruiting	No outcome recorded
Phase 1/2	NCT06545890	Aug → Nov 2024 overdue	delirium	Cairo University	Recruiting	No outcome recorded
Phase 1/2	NCT06036511	Dec 2023	post-traumatic stress disorder	University of New Mexico	Withdrawn	No outcome recorded
Phase 1/2	NCT06031883	Feb 2023 → Dec 2024	—	Minia University	Completed	No outcome recorded
Phase 1/2	NCT04955470	Jun 2022 → Sep 2023	—	University of British Columbia	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT05168735	Feb 2022 → Aug 2023	major depressive disorder	Rebecca Price	Completed	No outcome recorded
Phase 1/2	NCT05156060	Jan 2022 → Dec 2025 overdue	head and neck carcinoma	Natalie Lockney	Recruiting	No outcome recorded
Phase 1/2	NCT04916548	Sep 2021 → Jul 2023	depressive disorder	Rebecca Price	Completed	No outcome recorded
Phase 1/2	NCT04141696	Jul 2021 → Mar 2024	—	National Institute of Nursing Research (NINR)	Completed	No outcome recorded
Phase 1/2	NCT04892251	May 2021 → Dec 2023 overdue	opiate dependence	University of Utah	Recruiting	No outcome recorded
Phase 1/2	NCT04589208	Jan 2021 → Jan 2027 expected	—	New York State Psychiatric Institute	Active not recruiting	No outcome recorded
Phase 1/2	NCT04388774	Aug 2020 → Jun 2021	ADNP-related multiple congenital anomalies - intellectual disability - autism spectrum disorder	Alexander Kolevzon	Completed	No outcome recorded
Phase 1/2	NCT04179266	Nov 2019 → May 2020	cluster headache syndrome	CCH Pharmaceuticals	Completed	No outcome recorded
Phase 1/2	NCT04471818	Sep 2019 → Jun 2023	major depressive disorder	National Cancer Institute of Mexico	Completed	No outcome recorded
Phase 1/2	NCT03813121	Jun 2019 → Aug 2021	nicotine dependence	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 1/2	NCT03960658	Apr → Nov 2019	post-traumatic stress disorder	Minneapolis Veterans Affairs Medical Center	Completed	No outcome recorded
Phase 1/2	NCT04242914	Feb 2019 → Feb 2021	—	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
Phase 1/2	NCT03500289	Aug 2018 → Aug 2019	multiple sclerosis	Johns Hopkins University	Completed	No outcome recorded
Phase 1/2	NCT03237286	Dec 2017 → Oct 2022	depressive disorder	Rebecca Price	Completed	Met primary
Phase 1/2	NCT03146806	Jul 2017 → Apr 2020	cancer	Emory University	Completed	No outcome recorded
Phase 1/2	NCT02422290	Mar 2015 → Feb 2018	obsessive-compulsive disorder	New York State Psychiatric Institute	Completed	Missed primary
Phase 1/2	NCT02258204	Mar 2015 → Dec 2017	stroke disorder	University Hospital, Caen	Unknown	No outcome recorded
Phase 1/2	NCT02461927	Jan 2015 → Oct 2023	alcohol dependence, major depressive disorder	VA Office of Research and Development	Completed	Missed primary
Phase 1/2	NCT01944293	Sep 2013 → Sep 2017	bipolar disorder, depressive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 1/2	NCT01573741	Feb → Dec 2012	major depressive disorder	Shi Jinyun	Unknown	No outcome recorded
Phase 1/2	NCT01535937	Feb 2012 → Jan 2017	cocaine dependence	New York State Psychiatric Institute	Terminated	No outcome recorded
Phase 1/2	NCT01089361	Dec 2009 → Jun 2010	infectious disease with sepsis	Beth Israel Deaconess Medical Center	Completed	No outcome recorded
Phase 1/2	NCT00088699	Jul 2004 → Jul 2017	major depressive disorder	National Institute of Mental Health (NIMH)	Completed	Met primary

Phase 2137 trials · 8 met primary · 2 missed
Phase 2	NCT05945147	Jan → Apr 2099	complex regional pain syndrome	Stanford University	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT07247006	Dec 2026 → Mar 2028 expected	atypical depressive disorder, chronic pain syndrome	University of Rochester	Not yet recruiting	No outcome recorded
Phase 2	NCT07868913	Sep 2026 → Sep 2028 expected	—	The University of Texas Health Science Center at San Antonio	Recruiting	No outcome recorded
Phase 2	NCT07369024	Sep 2026 → Dec 2027 expected	sickle cell disease	Mohsen Saidinejad	Recruiting	No outcome recorded
Phase 2	NCT07099534	Sep 2026 → Sep 2028 expected	borderline personality disorder	University Hospital, Toulouse	Not yet recruiting	No outcome recorded
Phase 2	NCT07112456	Sep 2026 → Aug 2029 expected	acute asthma	Oman Medical Speciality Board	Not yet recruiting	No outcome recorded
Phase 2	NCT07588802	Sep 2026 → Apr 2027 expected	—	Massachusetts General Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT06419985	Jul 2026 → Jan 2028 expected	complex regional pain syndrome	University of Southern California	Not yet recruiting	No outcome recorded
Phase 2	NCT07705022	Jul 2026 → Jan 2028 expected	—	University of Michigan	Not yet recruiting	No outcome recorded
Phase 2	NCT07569198	Jun 2026 → Jan 2029 expected	bipolar depression, borderline personality disorder, major depressive disorder	Joshua Rosenblat	Not yet recruiting	No outcome recorded
Show all 137 trials opens the full record — a long page
Phase 2/340 trials · 4 met primary · 4 missed
Phase 2/3	NCT07801703	Sep 2026 → Sep 2029 expected	major depressive disorder	The Royal's Institute of Mental Health Research	Not yet recruiting	No outcome recorded
Phase 2/3	NCT07670507	Jun → Dec 2026 expected	—	Albany Medical College	Not yet recruiting	No outcome recorded
Phase 2/3	NCT07276542	Jan → Dec 2026 expected	—	The Ketamine Research Foundation	Recruiting	No outcome recorded
Phase 2/3	NCT06048263	Oct 2025	postpartum depression	Washington University School of Medicine	Withdrawn	No outcome recorded
Phase 2/3	NCT07095842	Aug 2025 → Jul 2026 overdue	epilepsy syndrome	Sohag University	Recruiting	No outcome recorded
Phase 2/3	NCT07046611	Jul 2025 → Jun 2026 overdue	epilepsy with generalized tonic-clonic seizures	Sohag University	Recruiting	No outcome recorded
Phase 2/3	NCT06891300	Apr 2025 → Oct 2026 expected	major depressive disorder	The Royal's Institute of Mental Health Research	Recruiting	No outcome recorded
Phase 2/3	NCT03223220	Jul 2024 → Dec 2026 expected	ischemic stroke	Lower Merion Neurology Research Foundation	Not yet recruiting	No outcome recorded
Phase 2/3	NCT06364072	May 2024 → May 2025	—	Cessatech A/S	Completed	No outcome recorded
Phase 2/3	NCT05032118	Apr 2023	acquired aneurysmal subarachnoid hemorrhage	Jenna L Leclerc MD, PhD	Withdrawn	No outcome recorded
Phase 2/3	NCT05779657	Mar 2023 → Aug 2024	epilepsy with generalized tonic-clonic seizures	Sohag University	Completed	No outcome recorded
Phase 2/3	NCT05696691	Jan 2023 → Dec 2026 expected	—	The University of Texas Health Science Center at San Antonio	Recruiting	No outcome recorded
Phase 2/3	NCT04939987	Aug → Oct 2022	—	Wake Forest University Health Sciences	Withdrawn	No outcome recorded
Phase 2/3	NCT05343507	May 2022 → May 2025	—	University of Liege	Unknown	No outcome recorded
Phase 2/3	NCT04650074	Nov 2021 → Jan 2024	complex regional pain syndrome type 1, neuropathy, painful	Hospices Civils de Lyon	Completed	Missed primary
Phase 2/3	NCT03436121	Dec 2019 → Feb 2020	depressive disorder	Maria Pacella	Withdrawn	No outcome recorded Stop: Business
Phase 2/3	NCT03889756	Jul → Dec 2019	major depressive disorder	Yale University	Terminated	No outcome recorded Stop: Enrollment
Phase 2/3	NCT04216888	Jun 2019 → Dec 2020	major depressive disorder	Dan Iosifescu	Completed	No outcome recorded
Phase 2/3	NCT03553758	Nov 2018 → Feb 2019	—	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2/3	NCT02967640	May 2018 → Dec 2024	chronic pain syndrome, rotator cuff syndrome	Helse Møre og Romsdal HF	Completed	No outcome recorded
Phase 2/3	NCT03407404	Oct 2017 → Jun 2019	—	Makerere University	Terminated	No outcome recorded
Phase 2/3	NCT03086148	Jul 2017 → Aug 2018	—	Beijing Tiantan Hospital	Completed	Met primary
Phase 2/3	NCT03165149	Jun 2017 → Aug 2019	breast cancer	Assiut University	Completed	No outcome recorded
Phase 2/3	NCT03499886	Jan 2017 → Apr 2018	—	Isfahan University of Medical Sciences	Unknown	No outcome recorded
Phase 2/3	NCT03915938	Jan → Nov 2017	chronic pain syndrome, schizophrenia	Hospital de Clinicas de Porto Alegre	Completed	No outcome recorded
Phase 2/3	NCT02783430	Sep 2016 → Mar 2024	depressive disorder	University Hospital, Lille	Completed	No outcome recorded
Phase 2/3	NCT02636218	Jan 2016 → Mar 2021	subarachnoid hemorrhage	Unity Health Toronto	Completed	No outcome recorded
Phase 2/3	NCT03000413	Jun 2015 → Jun 2017	asthma	Hospital Nossa Senhora da Conceicao	Completed	No outcome recorded
Phase 2/3	NCT02514122	Jun → Jul 2015	—	University of Saskatchewan	Completed	Met primary
Phase 2/3	NCT02397889	May 2015 → Jan 2020	post-traumatic stress disorder	Icahn School of Medicine at Mount Sinai	Completed	Met primary
Phase 2/3	NCT02929524	Apr 2015 → Oct 2016	digestive system disorder, respiratory system disorder	Hospital de Clinicas de Porto Alegre	Completed	No outcome recorded
Phase 2/3	NCT02659085	Feb 2015 → Aug 2019	major depressive disorder	Pouya Movahed Rad	Completed	No outcome recorded
Phase 2/3	NCT02398136	Dec 2014	post-traumatic stress disorder	Adriana Feder	Withdrawn	No outcome recorded
Phase 2/3	NCT02452060	Oct 2014 → Apr 2017	—	NYU Langone Health	Completed	Missed primary
Phase 2/3	NCT02105415	Apr 2014 → Nov 2017	—	Mayo Clinic	Completed	Missed primary
Phase 2/3	NCT02099006	Nov 2013 → Jun 2015	female reproductive system disorder	University of Rochester	Completed	Missed primary
Phase 2/3	NCT02048423	Jun 2013 → Jun 2015	major depressive disorder	Nationwide Children's Hospital	Unknown	No outcome recorded
Phase 2/3	NCT01945047	May 2013 → Dec 2017	—	University of Ottawa	Completed	Met primary
Phase 2/3	NCT01807429	Dec 2012 → Jan 2013	dwarfism thin bones multiple fractures	Isfahan University of Medical Sciences	Completed	No outcome recorded
Phase 2/3	NCT02969733	Jan 2011 → Sep 2017	neuropathy, painful	University Hospital, Lille	Completed	No outcome recorded

Phase 3104 trials · 6 met primary · 8 missed
Phase 3	NCT07839338	Oct 2026 → Oct 2029 expected	depressive disorder	Jawaharlal Institute of Postgraduate Medical Education & Research	Not yet recruiting	No outcome recorded
Phase 3	NCT06835504	Sep 2026 → Aug 2029 expected	—	Columbia University	Not yet recruiting	No outcome recorded
Phase 3	NCT07627906	Jul → Dec 2026 expected	delirium	Cairo University	Recruiting	No outcome recorded
Phase 3	NCT07530146	May → Oct 2026 expected	infectious disease with sepsis, pneumonia	Helwan University	Recruiting	No outcome recorded
Phase 3	NCT06781697	May 2026 → Dec 2027 expected	—	Sunnybrook Health Sciences Centre	Not yet recruiting	No outcome recorded
Phase 3	NCT06907173	Mar 2026 → Jun 2029 expected	—	University of Virginia	Recruiting	No outcome recorded
Phase 3	NCT07450430	Feb 2026 → Feb 2029 expected	sickle cell disease	Boston Children's Hospital	Not yet recruiting	No outcome recorded
Phase 3	NCT07370181	Jan → Nov 2026 expected	—	Assiut University	Active not recruiting	No outcome recorded
Phase 3	NCT06767358	Oct 2025 → Nov 2027 expected	—	McMaster University	Not yet recruiting	No outcome recorded
Phase 3	NCT07165262	Aug 2025 → Mar 2027 expected	brain neoplasm, epilepsy	Children's Cancer Hospital Egypt 57357	Active not recruiting	No outcome recorded
Phase 3	NCT07088380	Jul 2025 → Aug 2026 overdue	major depressive disorder	Vita-Salute San Raffaele University	Recruiting	No outcome recorded
Phase 3	NCT06957704	May 2025 → Apr 2028 expected	depressive disorder	Federal University of São Paulo	Not yet recruiting	No outcome recorded
Phase 3	NCT05603104	Apr 2025 → Jun 2028 expected	bipolar depression, major depressive disorder, schizophrenia	Dr. Inge Winter	Recruiting	No outcome recorded
Phase 3	NCT06733129	Apr 2025 → Apr 2027 expected	—	Nantes University Hospital	Recruiting	No outcome recorded
Phase 3	NCT06464146	Feb 2025 → Feb 2028 expected	—	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 3	NCT06713616	Jan 2025 → Dec 2030 expected	depressive disorder	Yale University	Recruiting	No outcome recorded
Phase 3	NCT06508710	Oct 2024 → Mar 2026 overdue	major depressive disorder	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 3	NCT06752759	Oct 2024 → Sep 2027 expected	major depressive disorder	Theresa Jacob, PhD, MPH	Recruiting	No outcome recorded
Phase 3	NCT05973851	Aug 2024 → Jun 2028 expected	major depressive disorder	Dr. Inge Winter	Recruiting	No outcome recorded
Phase 3	NCT06383273	May → Dec 2024 overdue	cataract	Melt Pharmaceuticals	Recruiting	No outcome recorded
Phase 3	NCT05625555	Jan 2024 → Jul 2026 overdue	bipolar disorder, major depressive disorder	Abraham Nunes	Active not recruiting	No outcome recorded
Phase 3	NCT05783492	Jan → Mar 2024	—	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Withdrawn	No outcome recorded
Phase 3	NCT06140927	Dec 2023 → Dec 2026 expected	spinal stenosis	University of California, San Francisco	Recruiting	No outcome recorded
Phase 3	NCT05437575	Nov 2023 → Jul 2028 expected	—	Jason Sperry	Recruiting	No outcome recorded
Phase 3	NCT06122948	Nov 2023 → Oct 2024	adenoid hypertrophy, drug allergy, tonsillitis	Kasr El Aini Hospital	Completed	No outcome recorded
Phase 3	NCT05468840	Jun → Dec 2023	—	University of Ottawa	Unknown	No outcome recorded
Phase 3	NCT04833816	Aug 2022 → Oct 2025	—	Assistance Publique Hopitaux De Marseille	Completed	No outcome recorded
Phase 3	NCT05481281	Aug 2022 → Jan 2023	—	Hamdard University	Unknown	No outcome recorded
Phase 3	NCT04763343	Jun 2022 → Feb 2027 expected	—	Tatiana Falcone, MD	Recruiting	No outcome recorded
Phase 3	NCT05311722	Apr → Dec 2022	—	Sheikh Zayed Medical College	Unknown	No outcome recorded
Phase 3	NCT05233566	Apr 2022 → Mar 2023	—	Washington University School of Medicine	Completed	No outcome recorded
Phase 3	NCT04939649	Sep 2021 → Apr 2024	bipolar depression, major depressive disorder	University of Dublin, Trinity College	Completed	Missed primary
Phase 3	NCT04886453	Aug 2021 → Mar 2024	—	Centre Hospitalier Universitaire Dijon	Completed	Met primary
Phase 3	NCT04955158	Aug 2021 → Feb 2023	pharyngitis	Assiut University	Completed	No outcome recorded
Phase 3	NCT04144933	May 2021 → Jul 2024	paralytic ileus	University of Saskatchewan	Unknown	No outcome recorded
Phase 3	NCT04576975	Apr → Dec 2021	morbid obesity	Ain Shams University	Unknown	No outcome recorded
Phase 3	NCT05163366	Mar → Nov 2021	—	Mbarara University of Science and Technology	Completed	No outcome recorded
Phase 3	NCT04134052	Jan → May 2021	cognitive disorder	University of Colima	Unknown	No outcome recorded
Phase 3	NCT04646694	Nov 2020 → Mar 2023	—	University Health Network, Toronto	Completed	No outcome recorded
Phase 3	NCT04227704	Nov 2020 → Aug 2021	postpartum depression	Washington University School of Medicine	Completed	No outcome recorded
Phase 3	NCT04176419	Jan 2020 → Jun 2021	—	Case Comprehensive Cancer Center	Terminated	No outcome recorded
Phase 3	NCT04260607	Jan 2020 → Apr 2021	depressive disorder	Naval Medical Center Camp Lejeune	Terminated	No outcome recorded
Phase 3	NCT03338205	Jan 2020 → Dec 2021	status asthmaticus	Augusta University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT04081545	Dec 2019 → Mar 2023	substance-related disorder	Christine Oryhan	Completed	No outcome recorded
Phase 3	NCT03511833	Dec 2019 → Dec 2021	—	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
Phase 3	NCT05386069	Nov 2019 → Dec 2020	—	Prisma Health-Upstate	Completed	Met primary
Phase 3	NCT04084548	Oct 2019 → Dec 2025 overdue	—	The Cleveland Clinic	Active not recruiting	No outcome recorded
Phase 3	NCT04096768	Sep 2019 → Sep 2021	—	Lebanese American University Medical Center	Unknown	No outcome recorded
Phase 3	NCT06185127	Sep 2019 → May 2020	lung disorder	University of Patras	Completed	No outcome recorded
Phase 3	NCT04075006	Aug 2019 → May 2021	—	King Faisal Specialist Hospital & Research Center	Completed	No outcome recorded
Phase 3	NCT03051945	Aug 2019	major depressive disorder	University of Utah	Withdrawn	No outcome recorded
Phase 3	NCT03396601	Jun 2019 → Dec 2024	bipolar depression	NeuroRx, Inc.	Unknown	No outcome recorded
Phase 3	NCT03751423	Jun 2019 → Dec 2023	—	Dr. Marie Eve Sophie Bussiere-Cote	Suspended	No outcome recorded
Phase 3	NCT03674671	Oct 2018 → Dec 2025	bipolar depression, major depressive disorder	University of Ottawa	Suspended	No outcome recorded Stop: Business
Phase 3	NCT03502421	Sep 2018 → Sep 2019	chronic pain syndrome	University of South Florida	Withdrawn	No outcome recorded
Phase 3	NCT03525821	Jul 2018 → Sep 2020	—	Fondation Lenval	Completed	No outcome recorded
Phase 3	NCT03539887	May 2018 → Jan 2022	alcohol abuse, depressive disorder	The University of Texas Health Science Center, Houston	Completed	Missed primary
Phase 3	NCT01519154	Feb 2018 → Jun 2024	—	Achim Schmitz	Completed	No outcome recorded
Phase 3	NCT04322968	Jan 2018 → Jun 2019	chronic pain syndrome, post-traumatic stress disorder	VA Ann Arbor Healthcare System	Completed	No outcome recorded
Phase 3	NCT03236805	Nov 2017 → Nov 2022	—	Nantes University Hospital	Terminated	Met primary Stop: Enrollment
Phase 3	NCT02987985	Oct 2017 → Sep 2019	obstructive sleep apnea syndrome, respiratory underresponsiveness to hypoxia and hypercapnia	University of Saskatchewan	Completed	No outcome recorded
Phase 3	NCT02828566	Oct 2017 → Jan 2019	disease of bone structure	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Unknown	No outcome recorded
Phase 3	NCT02950233	May 2017 → Dec 2018	neuropathy, painful	Population Health Research Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02920528	May 2017 → Jun 2018	chronic pain syndrome	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Completed	Met primary
Phase 3	NCT03104140	Apr 2017 → Apr 2018	infectious disease with sepsis	Cairo University	Completed	No outcome recorded
Phase 3	NCT02892916	Mar 2017 → Aug 2019	—	Assistance Publique - Hôpitaux de Paris	Completed	Missed primary
Phase 3	NCT02532153	Feb 2017	—	Massachusetts General Hospital	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT02752477	Aug 2016 → Sep 2020	chronic pain syndrome	Ben Lim	Unknown	No outcome recorded
Phase 3	NCT02418702	Aug 2016	depressive disorder	United States Naval Medical Center, San Diego	Withdrawn	No outcome recorded
Phase 3	NCT02735343	Aug 2016 → May 2017	headache disorder	Mike O'Callaghan Military Hospital	Terminated	Missed primary
Phase 3	NCT02801292	Jul 2016 → Jul 2018	sickle cell disease	Augusta University	Unknown	No outcome recorded
Phase 3	NCT03081416	May → Sep 2016	headache disorder	Brooke Army Medical Center	Completed	No outcome recorded
Phase 3	NCT02778880	Mar 2016 → Feb 2017	—	Children's Hospital Medical Center, Cincinnati	Completed	Met primary
Phase 3	NCT02402868	Jan 2016 → Jan 2018	disease of bone structure	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Completed	No outcome recorded
Phase 3	NCT02556606	Oct 2015 → Mar 2020	major depressive disorder	VA Office of Research and Development	Completed	No outcome recorded
Phase 3	NCT02431663	Apr 2015 → Mar 2020	—	Meyer Children's Hospital IRCCS	Terminated	No outcome recorded
Phase 3	NCT02299440	Apr 2015 → Nov 2019	—	Nîmes University Hospital	Completed	No outcome recorded
Phase 3	NCT02591017	Feb 2015 → Jul 2017	—	University Hospital, Basel, Switzerland	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02079090	Jul 2014 → Jun 2017	—	University of British Columbia	Completed	No outcome recorded
Phase 3	NCT02150161	May 2014 → Aug 2015	—	Clinica Santa Maria	Terminated	No outcome recorded
Phase 3	NCT02062879	Apr 2014 → Jun 2016	—	University of Cincinnati	Terminated	No outcome recorded
Phase 3	NCT01690988	Feb 2014 → Jun 2016	delirium	Washington University School of Medicine	Completed	Missed primary
Phase 3	NCT02037503	Jan 2014 → May 2020	major depressive disorder	Tel-Aviv Sourasky Medical Center	Unknown	Met primary
Phase 3	NCT02011347	Jul 2013 → Oct 2015	—	Hopital Foch	Terminated	No outcome recorded
Phase 3	NCT01724983	Jun 2012 → Jun 2014	morbid obesity	University of Padova	Unknown	No outcome recorded
Phase 3	NCT01557712	Mar 2012 → Jan 2017	major depressive disorder	University Hospital, Grenoble	Completed	No outcome recorded
Phase 3	NCT01517828	Jan 2012 → May 2016	respiratory distress syndrome in premature infants	University Hospital, Montpellier	Unknown	No outcome recorded
Phase 3	NCT01326325	Jul 2011 → Feb 2013	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT01983020	Apr 2011 → Jan 2013	—	Beth Israel Medical Center	Completed	No outcome recorded
Phase 3	NCT00474110	Aug 2009 → Dec 2011	mucositis	University of British Columbia	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT01316744	Apr 2009 → Oct 2011	cancer	University of Glasgow	Unknown	No outcome recorded
Phase 3	NCT00709436	Jun 2008 → Aug 2011	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT00661063	Apr 2008 → Apr 2009	diabetic neuropathy	Irmandade da Santa Casa de Misericordia de Sao Paulo	Unknown	No outcome recorded
Phase 3	NCT00798083	Apr 2008 → Jul 2009	radiation-induced neuropathy	British Columbia Cancer Agency	Completed	No outcome recorded
Phase 3	NCT00516503	Feb 2008 → Apr 2009	cancer of unknown primary site, leukemia, lymphoproliferative syndrome, myelodysplastic syndrome +4	Alliance for Clinical Trials in Oncology	Completed	Missed primary
Phase 3	NCT00471445	Oct 2007 → Sep 2013	cancer of unknown primary site, chemotherapy-induced toxicity, peripheral neuropathy	Gary Morrow	Completed	Missed primary
Phase 3	NCT00492388	Jun 2007 → Aug 2011	cancer	Pfizer	Terminated	No outcome recorded Stop: Business
Phase 3	NCT00484484	May 2007 → Sep 2009	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT00329394	Apr 2006 → Sep 2008	alcohol-induced mental disorder, head and neck carcinoma	University Hospital, Clermont-Ferrand	Suspended	No outcome recorded
Phase 3	NCT00146926	Sep 2005 → ?	—	Hospices Civils de Lyon	Unknown	No outcome recorded
Phase 3	NCT00313378	Apr 2004 → May 2008	—	University Hospital, Clermont-Ferrand	Completed	Missed primary
Phase 3	NCT00210210	Jan 2004 → Jul 2005	breast cancer	Institut Bergonié	Completed	No outcome recorded
Phase 3	NCT00224692	Feb 2003 → Aug 2006	cancer, mucositis	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 3	NCT00224588	Jan 2003 → May 2005	neuralgia	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded

Phase 4209 trials · 9 met primary · 16 missed
Phase 4	NCT07855523	Nov 2026 → Nov 2027 expected	—	Assiut University	Not yet recruiting	No outcome recorded
Phase 4	NCT07826988	Oct 2026 → Oct 2029 expected	sickle cell disease	Assistance Publique - Hôpitaux de Paris	Not yet recruiting	No outcome recorded
Phase 4	NCT07855068	Oct 2026 → Oct 2027 expected	nephrolithiasis	Assiut University	Not yet recruiting	No outcome recorded
Phase 4	NCT07680140	Aug 2026 → Sep 2028 expected	major depressive disorder	Weill Medical College of Cornell University	Recruiting	No outcome recorded
Phase 4	NCT07682662	Aug 2026 → Aug 2029 expected	sickle cell disease	University of Mississippi Medical Center	Not yet recruiting	No outcome recorded
Phase 4	NCT07670052	Aug 2026 → Jun 2027 expected	—	Assiut University	Not yet recruiting	No outcome recorded
Phase 4	NCT07139106	May 2026 → May 2028 expected	major depressive disorder	New York State Psychiatric Institute	Not yet recruiting	No outcome recorded
Phase 4	NCT07365800	Apr → Dec 2026 expected	upper thoracic spina bifida aperta	University of Missouri-Columbia	Enrolling by invitation	No outcome recorded
Phase 4	NCT07513935	Mar → Sep 2026 overdue	—	Ain Shams University	Active not recruiting	No outcome recorded
Phase 4	NCT07182032	Feb 2026 → Jun 2028	chronic pain syndrome, endometriosis	University Hospitals Cleveland Medical Center	Withdrawn	No outcome recorded
Show all 209 trials opens the full record — a long page
Phase not applicable153 trials · 3 met primary · 3 missed
—	NCT07435493	Nov 2026 expected	adenoid hypertrophy, obstructive sleep apnea syndrome	Ain Shams University	Not yet recruiting	No outcome recorded
—	NCT07810023	Sep 2026 → Mar 2027 expected	major depressive disorder	Endeavor Health	Enrolling by invitation	No outcome recorded
—	NCT07806162	Sep → Oct 2026 expected	—	Sohag University	Not yet recruiting	No outcome recorded
—	NCT07746115	Aug 2026	—	Aswan University Hospital	Completed	No outcome recorded
—	NCT07708740	Jul 2026 → Dec 2027 expected	—	Cairo University	Recruiting	No outcome recorded
—	NCT07636070	Jun → Aug 2026 overdue	urolithiasis	murat sahin	Not yet recruiting	No outcome recorded
—	NCT06963294	May → Jun 2026 overdue	delirium, subjective cognitive decline	Istinye University	Not yet recruiting	No outcome recorded
—	NCT06738043	Apr 2026 → Apr 2027 expected	obesity disorder	Tanta University	Not yet recruiting	No outcome recorded
—	NCT07197684	Mar → Dec 2026 expected	breast cancer, chronic pain syndrome	Aga Khan University	Not yet recruiting	No outcome recorded
—	NCT07385352	Mar → Aug 2026 overdue	developmental dysplasia of the hip	Assiut University	Not yet recruiting	No outcome recorded
Show all 153 trials opens the full record — a long page
Comparator or background therapy445 trials
Phase 0	NCT07408193 Comparator	Mar 2026 → Aug 2027 expected	refractory malignant neoplasm	National and Kapodistrian University of Athens	Recruiting	No outcome recorded
Phase 0	NCT06368219 Comparator	Apr → Sep 2024	—	Alexandria University	Unknown	No outcome recorded
Phase 0	NCT06064162 Comparator	Dec 2023 → May 2025	multiple sclerosis	Alta Bates Summit Medical Center	Completed	No outcome recorded
Phase 0	NCT05671913 Comparator	Jan 2023 → Dec 2025	—	Sanford Health	Withdrawn	No outcome recorded Stop: Business
Phase 0	NCT05315271 Comparator	Jun 2022 → Jan 2023	—	Sohag University	Completed	No outcome recorded
Show all 445 trials opens the full record — a long page

Press releases naming this drug 83 releases

Date	Issuer	Release
2026-07-21	PharmaTher Inc.	PharmaTher Enters into Collaboration Agreement for KetaMist® to Advance Needle-Free Ketamine Treatment Toward FDA Approval pharmather.com ↗
2026-07-21	PharmaTher Inc.	PharmaTher Enters into Collaboration Agreement for KetaMist® to Advance Needle-Free Ketamine Treatment Toward FDA Approval pharmather.com ↗
2026-07-07	HolsboerMaschmeyer NeuroChemie GmbH	HMNC Brain Health Announces Publication of Ketabon (KET01) Clinical Trial Results in JAMA Network Open hmnc-brainhealth.com ↗
2026-04-21	PharmaTher Inc.	PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness pharmather.com ↗
2026-02-02	PharmaTher Inc.	PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success pharmather.com ↗
2026-01-14	PharmaTher Inc.	PharmaTher Expands PharmaPatch™ Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs pharmather.com ↗
2025-12-02	PharmaTher Inc.	PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise pharmather.com ↗
2025-11-17	PharmaTher Inc.	PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program pharmather.com ↗
2025-10-17	PharmaTher Inc.	PharmaTher Applauds FDA’s Commissioner’s National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale pharmather.com ↗
2025-10-15	PharmaTher Inc.	PharmaTher Announces KetAImine™ — AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings pharmather.com ↗
2025-10-14	HolsboerMaschmeyer NeuroChemie GmbH	Ketabon Presents New Data Showing Antidepressant Effects of Oral Ketamine (KET01) Are Independent of Dissociation hmnc-brainhealth.com ↗
2025-10-08	PharmaTher Inc.	PharmaTher Provides Update on Ketamine Program for LID-Parkinson’s Disease pharmather.com ↗
2025-10-02	PharmaTher Inc.	PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy pharmather.com ↗
2025-10-01	PharmaTher Inc.	PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments pharmather.com ↗
2025-08-27	PharmaTher Inc.	PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine, Aligned with FDA’s CNPV National Priority Initiative pharmather.com ↗
2025-08-26	PharmaTher Inc.	PharmaTher Provides Corporate Update Following FDA Approval of Ketamine pharmather.com ↗
2025-08-11	PharmaTher Inc.	PharmaTher Announces FDA Approval of Ketamine pharmather.com ↗
2025-07-02	PharmaTher Inc.	PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine pharmather.com ↗
2025-06-24	PharmaTher Inc.	PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market pharmather.com ↗
2025-06-18	PharmaTher Inc.	PharmaTher Applauds FDA's New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications pharmather.com ↗
2025-05-16	PharmaTher Inc.	PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025 pharmather.com ↗
2025-05-14	PharmaTher Inc.	PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization pharmather.com ↗
2025-03-03	PharmaTher Inc.	PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine pharmather.com ↗
2025-02-12	PharmaTher Inc.	PharmaTher Provides Update on FDA New Drug Application for Ketamine pharmather.com ↗
2024-11-26	PharmaTher Inc.	PharmaTher Announces Update on FDA New Drug Application for Ketamine pharmather.com ↗
2024-11-19	PharmaTher Inc.	PharmaTher Announces Update on FDA New Drug Application for Ketamine pharmather.com ↗
2024-11-13	PharmaTher Inc.	PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application pharmather.com ↗
2024-09-17	HolsboerMaschmeyer NeuroChemie GmbH	Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At ECNP Congress 2024 hmnc-brainhealth.com ↗
2024-09-04	PharmaTher Inc.	PharmaTher Announces Update on FDA New Drug Application for Ketamine pharmather.com ↗
2024-05-21	HolsboerMaschmeyer NeuroChemie GmbH	Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting hmnc-brainhealth.com ↗
2024-05-10	PharmaTher Inc.	PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine pharmather.com ↗
2024-04-16	PharmaTher Inc.	PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine pharmather.com ↗
2024-02-12	PharmaTher Inc.	PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine pharmather.com ↗
2024-01-10	PharmaTher Inc.	PharmaTher Provides Update for Expected FDA Approval of Ketamine pharmather.com ↗
2023-11-13	HolsboerMaschmeyer NeuroChemie GmbH	Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression hmnc-brainhealth.com ↗
2023-11-06	Nephron Pharmaceuticals Corporation	NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression nephronpharm.com ↗
2023-09-27	PharmaTher Inc.	PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for Ketamine pharmather.com ↗
2023-09-06	PharmaTher Inc.	PharmaTher Submits Priority Original Abbreviated New Drug Application for Ketamine to the FDA pharmather.com ↗
2023-08-14	HolsboerMaschmeyer NeuroChemie GmbH	Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression hmnc-brainhealth.com ↗
2023-08-14	Develco Pharma Schweiz AG	Towards a Better-Tolerated Ketamine Treatment for Depression! develco.ch ↗
2023-06-27	PharmaTher Inc.	PharmaTher Initiates Filing of Abbreviated New Drug Application for Racemic Ketamine to the FDA pharmather.com ↗
2023-06-20	PharmaTher Inc.	PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of Racemic Ketamine in the U.S. pharmather.com ↗
2023-05-02	PharmaTher Inc.	PharmaTher Holdings Submits Fast Track Application to FDA for Ketamine for the Treatment of Parkinson’s Disease pharmather.com ↗
2023-03-29	PharmaTher Inc.	PharmaTher Holdings Announces Update of Type C Meeting with the FDA for Ketamine in Parkinson’s Disease pharmather.com ↗
2023-03-28	HolsboerMaschmeyer NeuroChemie GmbH	HMNC BRAIN HEALTH AND DEVELCO PHARMA ANNOUNCE LAST PATIENT BEING RANDOMIZED IN ORAL PROLONGED-RELEASE KETAMINE (KET01) TRIAL FOR TREATMENT-RESISTANT DEPRESSION hmnc-brainhealth.com ↗
2023-03-28	Develco Pharma Schweiz AG	Last patient being randomized in oral prolonged-release ketamine trial for Treatment-Resistant Depression! develco.ch ↗
2023-02-07	PharmaTher Inc.	PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of Ketamine On-Body Pump System pharmather.com ↗
2023-02-01	PharmaTher Inc.	PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for Ketamine in Parkinson’s Disease pharmather.com ↗
2023-01-18	PharmaTher Inc.	PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome pharmather.com ↗
2023-01-11	PharmaTher Inc.	PharmaTher Holdings Provides Update for Racemic Ketamine Development Programs and Expected Milestones for 2023 pharmather.com ↗
2022-12-21	Harrow Inc	Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study harrow.com ↗
2022-12-15	PharmaTher Inc.	PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation pharmather.com ↗
2022-11-14	PharmaTher Inc.	PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience pharmather.com ↗
2022-11-01	PharmaTher Inc.	PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome pharmather.com ↗
2022-09-16	PharmaTher Inc.	PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress pharmather.com ↗
2022-09-07	PharmaTher Inc.	PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with Ketamine Patch pharmather.com ↗
2022-07-13	PharmaTher Inc.	PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders pharmather.com ↗
2022-06-29	PharmaTher Inc.	PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch pharmather.com ↗
2022-06-08	HolsboerMaschmeyer NeuroChemie GmbH	First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD) hmnc-brainhealth.com ↗
2022-05-25	PharmaTher Inc.	PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO pharmather.com ↗
2022-04-12	PharmaTher Inc.	PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs pharmather.com ↗
2022-03-31	HolsboerMaschmeyer NeuroChemie GmbH	HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-Resistant Depression (TRD), suggesting antidepressant efficacy and showing Placebo-Level Dissociative Side Effects in Phase 2 oral prolonged-release Ketamine (KET01) Study hmnc-brainhealth.com ↗
2022-03-23	PharmaTher Inc.	PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease pharmather.com ↗
2022-02-16	PharmaTher Inc.	PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation pharmather.com ↗
2022-02-01	PharmaTher Inc.	PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus pharmather.com ↗
2022-01-12	PharmaTher Inc.	PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS pharmather.com ↗
2021-12-20	PharmaTher Inc.	PHARMATHER ENTERS INTO PROCESS DEVELOPMENT AGREEMENT WITH LTS LOHMANN FOR KETAMINE MICRONEEDLE PATCH pharmather.com ↗
2021-11-30	PharmaTher Inc.	PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio pharmather.com ↗
2021-11-24	PharmaTher Inc.	PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus pharmather.com ↗
2021-10-19	PharmaTher Inc.	PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products pharmather.com ↗
2021-10-13	PharmaTher Inc.	PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome pharmather.com ↗
2021-10-06	PharmaTher Inc.	PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease pharmather.com ↗
2021-07-21	PharmaTher Inc.	PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation pharmather.com ↗
2021-05-25	PharmaTher Inc.	PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease pharmather.com ↗
2021-05-20	PharmaTher Inc.	Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs pharmather.com ↗
2021-05-17	PharmaTher Inc.	PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease pharmather.com ↗
2021-04-27	PharmaTher Inc.	PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™ pharmather.com ↗
2021-04-20	PharmaTher Inc.	PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson’s Disease pharmather.com ↗
2021-03-02	PharmaTher Inc.	PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig's Disease pharmather.com ↗
2021-02-04	PharmaTher Inc.	PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson’s Disease pharmather.com ↗
2021-01-19	PharmaTher Inc.	PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders pharmather.com ↗
2020-12-10	PharmaTher Inc.	PharmaTher Granted Pre-IND Meeting with the FDA for Ketamine in Parkinson’s Disease pharmather.com ↗
2018-04-10	Harrow Inc	Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting harrow.com ↗

Evidence & citations 42 cited values

Every value below carries the sentence it was read from. 1,253 sources stand behind the page.

Field	Value	Cited text
Known as	Kétamine	“Before operation, all patients will receive Groups M and D, K will receive an oral administration of 0.2 mg/kg of midazolam (up to a maximum of 15 mg) and 4 µg/kg of...” NCT06879496 ↗ 1217 “patients who will receive intravenous (I.V.) ketamine in a dose of 0.25 mg/kg diluted in 5 ml normal saline plus dexmetedomidine 0.25ug/kg followed by infusion of...” NCT07513935 ↗ “Ketamine produces dissociative anesthesia and sympathetic stimulation which provides more stable hemodynamic profile; however, ketamine is not widely used as a routine hypnotic...” NCT05166330 ↗ “General anesthesia without intraoperative opioids using dexmedetomidine, ketamine, lidocaine, sevoflurane, non-opioid co-analgesics, procedure-specific regional analgesia, and...” NCT07665463 ↗ “Opioid-Free Multimodal Analgesia will receive preoperative acetaminophen (15 mg/kg) and ibuprofen (10 mg/kg), intraoperative ketamine (0.5 mg/kg IV) and dexamethasone (0.1...” NCT07435493 ↗ “Ketamine, an FDA approved anesthetic agent, is becoming the sedative/analgesic of choice for emergency sedation in children because it causes deep sedation with minimal...” NCT00205712 ↗ “Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day,...” NCT06381063 ↗ “The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but...” NCT04890418 ↗ “Intravenous Induction of Anesthesia Using a Mixture of Ketamine and dexmedetomidine in a ratio of 1 mg ketamine to 0.5 ug dexmedetomidine given in a dose of 1mg/kg ketamine and...” NCT07002073 ↗ “NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10...” NCT02950233 ↗ “Open-label, Prospective Study to Assess the Safety, Tolerability, Analgesic Effect and Feasibility of Intranasal Sufentanil/Ketamine in Pediatric Patients With Moderate or...” NCT06364072 ↗ Show 1,207 more sources
Known as	dexter ketamine	“Drug: dexter ketamine” NCT02953210 ↗
Known as	INK	“The purpose of this study is to determine if Intranasal Ketamine (INK) is efficacious for Procedural Sedation and Analgesia (PSA) when compared to Intravenous Ketamine (IVK) in...” NCT03781817 ↗
Known as	IVK	“The purpose of this study is to determine if Intranasal Ketamine (INK) is efficacious for Procedural Sedation and Analgesia (PSA) when compared to Intravenous Ketamine (IVK) in...” NCT03781817 ↗
Known as	KET	“The purpose of this study is to examine the effectiveness of a single infusion of ketamine (KET), to determine which dose is optimal 7 days after infusion using Bayesian...” NCT02556606 ↗ 7 “The clinical team will test whether the effects of ketamine (KET) on mood and psychotic states is modified by co-administration with sodium nitroprusside (NP) in patients with...” NCT03102736 ↗ “Subanesthetic dose of intravenous ketamine (KET) has been found to be highly effective in rapid treatment depression” NCT06698848 ↗ “All participants will receive three intravenous (IV) Ketamine (KET) infusions over 7 days.” NCT03290963 ↗ “Ketamine (KET) has been used for decades as a sedative and anesthetic.” NCT01945047 ↗ “Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET)” NCT06907173 ↗ “Subanesthetic dose intravenous ketamine (KET)” NCT06034821 ↗ “Group A will receive rectal ketamine(Ket)” NCT05163366 ↗
Known as	KET01	“Treatment with Ketamine Hydrochloride Prolonged-Release Tablets (KET01, 240 mg)” NCT07396272 ↗
Known as	ketalar	“Ketamine (ketalar®) will be administrated by intravenous route in 1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.” NCT04621110 ↗ 20 “Its hydrochloride salt is marketed under many brand names such as Ketanest, Ketalar, or Ketaset.” NCT02494830 ↗ “Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline” NCT04429685 ↗ “Ketamine 1 mg /kg(ketalar Vial 50mg/ml pfzer com) will be administered IV before induction” NCT07074262 ↗ “single dose IV Ketamine (Ketalar) 0.5mg/kg in 100ml Normal Saline infused over 40 minutes” NCT04260607 ↗ “0.5mg/kg of ketalar (ketamine). Single, intravenous, steady state infusion over 40min.” NCT04656886 ↗ “Single administration of Ketalar® (ketamine hydrochloride injection, USP); 5 mg/kg, IM” NCT03375671 ↗ “Ketalar (Ketamin, Pfizer) and Dormicum (Midazolam, Roche)” NCT02732132 ↗ “Ketamine (Ketalar, an FDA-approved drug for anesthesia)” NCT02252432 ↗ “Ketamine (Ketalar) Dose Level 1” NCT05907213 ↗ “Drug: Ketamine (Ketalar)” NCT05105061 ↗ Show 10 more sources
Known as	Ketamin	“Ketalar (Ketamin, Pfizer) and Dormicum (Midazolam, Roche)” NCT02732132 ↗ 1 NCT06698848 ↗
Known as	Ketamine (Hydrochloride) HCL	“Participants will be randomized to (1) Ketamine (Hydrochloride) HCL; (2) psychotherapy (using Cognitive Behavioral Therapy); or (3) a combination of Ketamine HL and psychotherapy.” NCT05639322 ↗
Known as	Ketamine (Ketalar) 50mg/mL injection	“Ketamine (Ketalar) 50mg/mL injection” NCT02267980 ↗
Known as	KETAMINE 50 mg/ml ATC N01AX03 Marketing Authorisation number 47034	“KETAMINE 50 mg/ml ATC N01AX03 Marketing Authorisation number 47034” NCT02909049 ↗
Known as	ketamine HCl	“Group A received PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1) while Group B received PCA morphine (Pfizer Inc., US) 1 mg ml-1 as...” NCT06021717 ↗ 6 “10mg/kg of Ketamine Hcl 100Mg/Ml Inj to be administered intranasally for pediatric procedural sedation” NCT03067974 ↗ “IV NRX-100 (ketamine HCL) for rapid stabilization of symptoms of depression and suicidal ideation” NCT03396601 ↗ “PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)” NCT06010056 ↗ “Ketamine-HCL IV 1mg/kg (up to 100 mg) over 2 hours, on weeks 2, 7, and 12.” NCT05639322 ↗ “PMI-150 (intranasal ketamine HCl)” NCT00662883 ↗ “Ketamine Hcl 50Mg/Ml Inj” NCT03499886 ↗
Known as	Ketamine HCl Prolonged Release	“Administration of Ketamine HCl Prolonged Release - 40mg BID” NCT06419985 ↗
Known as	Ketamine Hydrochloride	“In this pilot study, 0.5 mg/kg of intramuscular ketamine hydrochloride will be administered to a dosing cohort of 8 participants experiencing acute suicidal distress associated...” NCT07810023 ↗ 72 “Patients will be given ultrasound guided, modified Pecs block with 30 mL of 0.25% bupivacaine hydrochloride (Markyrene ®Sigma Tec, Egypt) plus ketamine hydrochloride (1 mg/kg)...” NCT05410158 ↗ “This double-blind, crossover, placebo-controlled study analyzed data from 18 drug-free major depressive disorder subjects and 18 heathy controls who received a single i.v....” PMID 29668918 ↗ Aug 2018 “METHODS: In a randomized, double-blind, crossover study, 20 patients with major depression were randomly assigned, and 18 completed 2 treatment days with intranasal ketamine...” PMID 24821196 ↗ Apr 2014 “A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of 10 mg, 30 mg, and 50 mg of Transnasal Ketamine Hydrochloride (PMI-100) for the...” NCT00488787 ↗ “The study agent is a mouthwash preparation of ketamine hydrochloride 20mg/5ml in NovaFilm suspension with OraSweet flavoring agent, which will be administered via swish and...” NCT05331131 ↗ “Ketamine hydrochloride (1 mg/kg) added to bupivacaine 0.25% (0.5 mL/kg) administered by ultrasound-guided quadratus lumborum block during open pyeloplasty.” NCT07596810 ↗ “in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect.” NCT03349216 ↗ “subjects were given an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart.” PMID 16894061 ↗ Aug 2006 “Ketamine hydrochloride 1 mg/kg administered as an adjuvant with 0.25% bupivacaine during ultrasound-guided bilateral TAP block.” NCT07845643 ↗ “comparing ketamine hydrochloride (20 mg, followed by 10 mg every 5 minutes) with morphine sulfate (2 or 3 mg every 5 minutes)” PMID 38285446 ↗ Jan 2024 Show 62 more sources
Known as	Ketamine hydrochloride (Ketamin Inresa 2 ml)	“Ketamine hydrochloride (Ketamin Inresa 2 ml)” NCT06410599 ↗
Known as	Ketamine hydrochloride, Ketalar	“Ketamine hydrochloride, Ketalar” NCT07536633 ↗
Known as	Ketamine hydrochrolide 50mg/ml,Nirma Pharmaceuticals (India)	“Ketamine hydrochrolide 50mg/ml,Nirma Pharmaceuticals (India)” NCT02434939 ↗
Known as	Ketamine PR	“All subjects will start with 40mg BID of Ketamine PR (80 mg/day) on the Baseline visit.” NCT06419985 ↗
Known as	Ketamine Sigma-Tec	“Patients will be given ultrasound guided, modified Pecs block with 30 mL of 0.25% bupivacaine hydrochloride (Markyrene ®Sigma Tec, Egypt) plus ketamine hydrochloride (1 mg/kg)...” NCT05410158 ↗
Known as	Ketamine sulphate	“Group B:Ketamine group(25 patients) will receive 0.5 mg/Kg ketamine sulphate in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed...” NCT06184958 ↗
Known as	Ketamine, Ketamin (Cristalia Lab, Sao Paulo, Brazil)	“Ketamine, Ketamin ® (Cristalia Lab, Sao Paulo, Brazil)” NCT02284204 ↗
Known as	Ketanest	“Its hydrochloride salt is marketed under many brand names such as Ketanest, Ketalar, or Ketaset.” NCT02494830 ↗
Known as	Ketanest-S	“Patients will receive either nebulized placebo (i.e. saline) or ketamine (Ketanest-S) when they require pain alleviation in the PACU.” NCT02397356 ↗
Known as	Ketaset	“Its hydrochloride salt is marketed under many brand names such as Ketanest, Ketalar, or Ketaset.” NCT02494830 ↗
Known as	Ketolar	“It is composed by Dexmedetomidine (Dexdor), Lidocaine, Magnesium Sulfate and ketamine (Ketolar).” NCT05887258 ↗
Known as	LDK	“Patients were consented and randomized to receive, either IV ketamine (LDK) 1 mg/kg or IV morphine (MOR) 0.1 mg/kg as an infusion over 10 min.” PMID 29794277 ↗ Jan 2018
Known as	nKTM	“OBJECTIVE: To compare the effectiveness of sedation by intranasal administration of midazolam (nMDZ) or ketamine (nKTM) for neonatal intubation.” PMID 28818854 ↗ Aug 2017
Known as	NRX-100	“IV NRX-100 (ketamine HCL) for rapid stabilization of symptoms of depression and suicidal ideation” NCT03396601 ↗
Known as	PMI-100	“A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of 10 mg, 30 mg, and 50 mg of Transnasal Ketamine Hydrochloride (PMI-100) for the...” NCT00488787 ↗
Known as	PMI-150	“30 mg PMI-150 (intranasal ketamine)” NCT00519987 ↗ 3 “PMI-150 (intranasal ketamine)” NCT00709436 ↗ “PMI-150 (intranasal ketamine)” NCT00492388 ↗ NCT00662883 ↗
Known as	R,S-ketamine	“Subanesthetic-dose racemic (R,S)-ketamine (ketamine) produces rapid, robust, and sustained antidepressant effects in major depressive disorder (MDD) and bipolar disorder (BD)...” PMID 35501309 ↗ May 2022 2 “Participants will undergo one infusion of ketamine as active comparator. (R,S-ketamine 50mg/ml solution for injection, dose: 0,5 mg per kg bodyweight)” NCT05577585 ↗ “intranasal (IN) racemic (R,S)-ketamine had antisuicidal and antidepressant effects” PMID 38696221 ↗ Apr 2024
Known as	Racemic ketamine	“Racemic ketamine (rketamine) is cheap and easy to access; however, the effects in patients who have not responded to electroconvulsive therapy have yet to be understood or tested.” PMID 34882570 ↗ Jan 2022 2 “Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study.” PMID 35738038 ↗ May 2022 “Patients will receive 0.5mg/kg Racemic ketamine IV over 40 min” NCT05019885 ↗
Known as	Racemic Ketamine Hydrochloride	“Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline” NCT04429685 ↗
Known as	rketamine	“Racemic ketamine (rketamine) is cheap and easy to access; however, the effects in patients who have not responded to electroconvulsive therapy have yet to be understood or tested.” PMID 34882570 ↗ Jan 2022
Known as	S (+) Ketamine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00354029 ↗ 4 NCT04834427 ↗ NCT00532662 ↗ NCT04837170 ↗ NCT02421913 ↗
Known as	S(+)-ketamine hydrochloride	“Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction, maintenance or postoperative analgesia.” NCT04834427 ↗
Known as	SDK	“sub-dissociative dose ketamine (SDK)” NCT03950817 ↗
Known as	Wafermine	“A Phase 2, Multiple-Dose Study of The Efficacy and Safety of Wafermine™ (Sublingual Ketamine) in Participants Experiencing Acute Post-Operative Bunionectomy or Abdominoplasty Pain” NCT03246971 ↗ 1 “single-dose Wafermine™ (ketamine sublingual wafer)” NCT07691372 ↗
Action	Inhibit	“This study will test whether a single dose of ketamine - a drug that blocks a brain receptor called NMDA - can cause a rapid (next day) antidepressant effect in patients with...” NCT00088699 ↗
Modality	Small molecule	“Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity.” NCT01517828 ↗
Route	Intravenous	“administered intravenously (through a vein) over 40 minutes” NCT00088699 ↗
Target	TNF	“Ketamine at low doses, below the normal anesthetic dose, appears to rapidly reduce the production of pro-inflammatory cytokines, especially IL-6 and tumor necrosis factor alpha...” NCT04365985 ↗